Partnerships - Additional Information (Details) $ in Thousands, ¥ in Billions	1 Months Ended		3 Months Ended		6 Months Ended		31 Months Ended
	Dec. 31, 2022 USD ($)	May 31, 2017 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Nov. 30, 2019 shares	Dec. 31, 2023 USD ($)	Aug. 03, 2023 USD ($)	Mar. 16, 2023 USD ($)	Mar. 16, 2023 JPY (¥)	Dec. 05, 2022 USD ($)	Dec. 05, 2022 JPY (¥)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Recognized revenue			$ 13,853	$ 9,124	$ 24,542	$ 18,003
Deferred revenue current			8,430		8,430			$ 15,729
Ono | Upfront Payment Amortization
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Recognized revenue			1,300		1,300
Ono | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Estimated research and development funding			76,800		76,800
Updation of estimated research and development funding			102,600		102,600
Ono | Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Estimated research and development funding			70,800		70,800
Updation of estimated research and development funding			96,600		$ 96,600
Ono | Asset Purchase Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront non-refundable and non-creditable payment receivable, upon exchange of option												$ 26,400	¥ 3.5
One-time payment receivable, upon exercises the option										$ 35,000	¥ 5.0
Option period expiry condition					the option period will expire 90 days following the delivery of topline data from the EQUALISE clinical study in lupus nephritis (LN) and the results of the interim analysis from the Phase 3 EQUATOR clinical study in aGVHD. In April 2024, the Company delivered topline data from the EQUALISE clinical study in LN to Ono, and on August 1, 2024 we delivered the results of the interim analysis from the Phase 3 EQUATOR clinical study in aGVHD to Ono, which results in the expiration of Ono's option period on October 30, 2024.
Upfront non-refundable and non-creditable payment invoiced												25,800	¥ 3.5
Upfront payment received	$ 26,400
Foreign curreny realized gain	$ 600
Initial transaction price												102,600
Upfront and non-creditable payment invoiced												25,800
Estimated research and development funding												76,800
Deferred revenue												$ 25,800
Recognized revenue			13,900	$ 9,100	$ 24,500	$ 18,000
Deferred revenue current			8,400		8,400
Proceeds from research and development fees					53,100
Ono | Asset Purchase Agreement | Research and Development Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Recognized revenue			9,200		17,200
Ono | Asset Purchase Agreement | Upfront Payment Amortization
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Recognized revenue			$ 4,700		$ 7,300
Ono | Asset Purchase Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eligible to receive payment on achievement of certain development milestones									$ 101,400
Biocon
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock shares issued | shares							2,316,134
Biocon | Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory milestone payments		$ 30,000
Sales milestone payments		$ 565,000